Product Center
Received national level praise!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-01
- Views:
(Summary description)Recently, recommended by the provincial adverse drug reaction monitoring institutions and comprehensively evaluated by the National Adverse Drug Reaction Monitoring Center, Ab&B Bio-Tech CO., LTD. JS has outstanding performance in fulfilling its main responsibilities in the monitoring of adverse drug reactions in 2023 and has been praised by the National Adverse Reaction Monitoring Center.
Received national level praise!
(Summary description)Recently, recommended by the provincial adverse drug reaction monitoring institutions and comprehensively evaluated by the National Adverse Drug Reaction Monitoring Center, Ab&B Bio-Tech CO., LTD. JS has outstanding performance in fulfilling its main responsibilities in the monitoring of adverse drug reactions in 2023 and has been praised by the National Adverse Reaction Monitoring Center.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-01 16:18
- Views:
Recently, recommended by the provincial adverse drug reaction monitoring institutions and comprehensively evaluated by the National Adverse Drug Reaction Monitoring Center, Ab&B Bio-Tech CO., LTD. JS has outstanding performance in fulfilling its main responsibilities in the monitoring of adverse drug reactions in 2023 and has been praised by the National Adverse Reaction Monitoring Center.
The achievement of the results fully reflects the affirmation of the preliminary work of Ab&B Bio-Tech CO.,LTD.JS by adverse drug reaction monitoring institutions at all levels, and Ab&B Bio-Tech CO.,LTD.JS will cherish the honor, continue to implement the "four strictest" requirements and the spirit of General Secretary Xi Jinping's series of important instructions on drug safety work, and perform their duties with a stronger sense of responsibility and mission, improve their pharmacovigilance ability, and contribute to the protection of public health!
Relevant information
-
The application for the marketing of trivalent influenza virus subunit vaccine has been accepted!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched! - Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
